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Abstract
Bimolecular fluorescence complementation (BiFC) was introduced a decade ago as a 
method to monitor alpha-synuclein (α-syn) oligomerization in intact cells. Since then, 
several α-syn BiFC cellular assays and animal models have been developed based on 
the assumption that an increase in the fluorescent signal correlates with increased 
α-syn oligomerization or aggregation. Despite the increasing use of these assays and 
models in mechanistic studies, target validation and drug screening, there have been 
no reports that (1) validate the extent to which the BiFC fluorescent signal correlates 
with α-syn oligomerization at the biochemical level; (2) provide a structural char-
acterization of the oligomers and aggregates formed by the BiFC. To address this 
knowledge gap, we first analysed the expression level and oligomerization properties 
of the individual constituents of α-syn-Venus, one of the most commonly used BiFC 
systems, in HEK-293 & SH-SY5Y cells from three different laboratories using multiple 
biochemical approaches and techniques. Next, we investigated the biochemical and 
aggregation properties of α-syn upon co-expression of both BiFC fragments. Our re-
sults show that (1) the C-terminal-Venus fused to α-syn (α-syn-Vc) is present in much 
lower abundance than its counterpart with N-terminal-Venus fused to α-syn (Vn-
α-syn); (2) Vn-α-syn exhibits a high propensity to form oligomers and higher-order 
aggregates; and (3) the expression of either or both fragments does not result in the 
formation of α-syn fibrils or cellular inclusions. Furthermore, our results suggest that 
only a small fraction of Vn-α-syn is involved in the formation of the fluorescent BiFC 
complex and that some of the fluorescent signal may arise from the association or en-
trapment of α-syn-Vc in Vn-α-syn aggregates. The fact that the N-terminal fragment 
exists predominantly in an aggregated state also indicates that one must exercise 
caution when using this system to investigate α-syn oligomerization in cells or in vivo. 
Altogether, our results suggest that cellular and animal models of oligomerization, 
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1  | INTRODUC TION
α-synuclein (α-syn) is a soluble protein that is highly expressed 
in neurons of the central nervous system (Fauvet et al., 2012; 
Lashuel, Overk, Oueslati, & Masliah, 2012). It is a member of the 
synuclein family of proteins, which includes two other shorter 
proteins, namely, β-syn and ɣ-syn. Although the three proteins 
share significant sequence homology, only α-syn has been shown 
to aggregate and accumulate in a fibrillar form in Lewy bodies 
and Lewy Neurites; the pathological hallmarks of Parkinson's 
disease (PD) as well as other neurodegenerative diseases includ-
ing Alzheimer's disease, dementia with Lewy bodies and multi-
ple system atrophy (Goedert, Jakes, & Spillantini, 2017). Under 
physiological conditions, α-syn shuttles between different or-
ganelles and exists in multiple conformations depending on its 
localization and interactions with other proteins, lipids and mem-
branes (Sulzer & Edwards, 2019). The transition of α-syn from a 
native state to its pathological forms requires it to undergo major 
conformational and quaternary structural changes involving a 
transition from disordered monomers to structured oligomers 
and then to β-sheet rich fibrillar aggregates (Figure 1b). Several 
cellular and animal models that reproduce different aspects of 
α-syn aggregation and pathology formation have been developed 
(Fares et al., 2016; Lee & Lee, 2002; Reyes et al., 2014; Volpicelli-
daley et al., 2011). However, the lack of tools that enable the 
monitoring of early events associated with α-syn misfolding and 
oligomerization has limited the utility of these models in inves-
tigating the molecular and cellular determinants of α-syn oligo-
mer formation and toxicity. Increasing evidence suggests that 
targeting early aggregation events, e.g., inhibiting α-syn oligo-
merization, represents one of the most effective strategies for 
preventing α-syn pathology formation and treating PD. The first 
step towards achieving this therapeutic goal is the development 
of robust cellular and animal models in which such early oligomer-
ization events could be visualized and quantified. Despite the re-
ported development of several antibodies that specifically detect 
α-syn oligomers, but not monomers or fibrils, none have emerged 
as a validated oligomer-specific or robust tool for monitoring 
and quantifying α-syn oligomerization in cellular models (Kumar 
et al., 2020). Although several groups report on the development 
and application of different assays to quantify α-syn oligomers, 
the majority of these assays do not differentiate the aggregation 
states of α-syn (oligomers vs. fibrils) or capture the diversity of 
α-syn oligomers and aggregates.
To allow monitoring of early oligomerization events (e.g. di-
merization) involving α-syn in living cells, Outeiro et al. (2008) 
developed an α-syn bimolecular fluorescent complementation 
(BiFC) assay. The main principle behind this assay is the fusion 
of N- and C-terminal fragments of a reporter protein (e.g. GFP 
or YFP) to the proteins of interest, which in this case are α-syn 
monomers. These fragments are not fluorescent when they are 
separated and only emit a fluorescence signal if the two frag-
ments are brought into close proximity to enable their association 
and the reconstitution of the structure of the full-length fluores-
cent protein; in this case, this occurs upon α-syn dimerization or 
oligomerization (Figure 1a) (Kerppola, 2006, 2008). It is worth 
pointing out that BiFC was initially developed to study heterod-
imeric protein interactions (Hu, Chinenov, & Kerppola, 2002; Hu 
& Kerppola, 2003), and its applications were later extended to 
investigate the self-assembly of amyloid-forming peptides and 
proteins (Outeiro et al., 2008).
The α-syn-BiFC system has been used to develop cellular assays to 
investigate several aspects of α-syn aggregation and biology, including 
(1) investigating the molecular and sequence determinants of α-syn 
oligomerization and aggregation (Aelvoet et al., 2014; Bae et al., 2014; 
Danzer et al., 2011, 2012; Delenclos et al., 2016; Gonçalves et al., 2016; 
Putcha et al., 2010; Savolainen, Yan, Myöhänen, & Huttunen, 2015; 
Tetzlaff et al., 2008; Zheng et al., 2018); (2) α-syn cell-to-cell trans-
mission and propagation (Bae et al., 2014; Kim et al., 2016); (3) the 
screening of genetic (Dettmer et al., 2015; Lázaro et al., 2014, 2016) 
and pharmacological modifiers (Dominguez-Meijide et al., 2020; 
Mohammadi, Nikkhah, & Hosseinkhani, 2017; Moussaud et al., 2015) 
of α-syn oligomerization, aggregation and clearance; and (4) the val-
idation of therapeutic targets (Outeiro et al., 2008). This approach 
was also extended to animal models of synucleinopathies, such as rats 
(Dimant et al., 2013), C. elegans (Kim et al., 2016) and, most recently, 
Drosophila (Prasad et al., 2018) and mice (Cai, Feng, Schwarzschild, 
McLean, & Chen, 2018; Kiechle et al., 2019).
While reviewing the literature, we noted the lack of data on 
(1) the biochemical validation of this system, that is evidence that 
reports on the formation of α-syn dimers, oligomers or higher-or-
der aggregates; (2) the stability and oligomerization properties 
of the BiFC fragments; (3) whether the fluorescent signal arises 
from an interaction between α-syn monomers only or between 
aggregation and cell-to-cell transmission based on the α-syn BiFC systems should be 
thoroughly characterized at the biochemical level to ensure that they reproduce the 
process of interest and measure what they are intended to measure.
K E Y W O R D S
aggregation, bimolecular fluorescent complementation, oligomerization, Parkinson's disease, 
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monomers of one fragment and oligomers or aggregates of the 
other fragment; and (4) the biochemical, structural or morpho-
logical properties of the oligomers/aggregates formed upon 
co-expression of the BiFC fragments and to what extent they 
compare to α-syn aggregates found in diseased brains or formed 
during the fibrillization of recombinant α-syn in vitro. To address 
F I G U R E  1   α-synuclein bimolecular fluorescence complementation (BiFC) assays: General principles and outstanding questions. (a) 
Schematic depiction of the individual BiFC fragments which emits fluorescence upon α-syn-dimerization/oligomerization mediated 
reconstitution of the fluorescent protein Venus. (b) A simplified representation of the mechanism of WT α-syn oligomerization, fibrillization 
and Lewy body formation. (c) Representation of the various possibilities for homo- and hetero-association between the BiFC fragments 
and that the scenarios that could lead to the generation of the BiFC fluorescence signal. From top to bottom: (i) Assumed α-syn BiFC 
oligomerization model, where the BIFC signal is generated upon α-syn dimerization/oligomerization mediated reconstitution of the 
fluorescent protein, Venus. What is not known is whether this dimer is capable of forming higher order oligomers and/or convert to amyloid 
fibrils. (ii) Possibility that one or both of the two constituents self-oligomerize on their own. (iii) Illustration of how interactions between one 
monomeric BiFC constituent with an aggregated/oligomerized species of its counterpart could also give rise to fluorescence signals and thus 
wrongly interpreted as being derived from two monomers. (iv) Reported drawback of BiFC: the formation of irreversible α-syn dimers with 
the reconstituted BiFC reporter that may not exhibit the same biophysical and oligomerization properties of native untagged α-syn. Vn-α-
syn: (amino terminal fraction of Venus)-α-syn; α-syn-Vc: α-syn-(carboxy terminal fraction of Venus)
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this knowledge gap, we performed a more in-depth characteriza-
tion of the α-syn-Venus BiFC system in HEK-293 & SH-SY5Y cells 
that were transfected by different techniques and originated from 
three different laboratories using a combination of biochemical 
and cellular assays. Our results show that differential expression 
of the fluorescent protein fragments and the high propensity of 
one of these fragments to self-associate on its own complicate 
the interpretation of the fluorescence signal in this BiFC cellular 
assay. These observations highlight the limitations of using this 
system to investigate mechanisms and modifiers of α-syn oligom-
erization or aggregation. They also underscore the critical impor-
tance of validating BiFC-based assays at both a biochemical and 
ultrastructural level. This is crucial to determine whether the BiFC 
assays accurately reproduce and report on the process of interest, 
prior to their use in investigating mechanisms of protein oligom-
erization, amyloid formation or cell-to-cell transmission modifiers 
of these processes.
2  | MATERIAL S AND METHODS
2.1 | Plasmids
The plasmid encoding WT-α-syn was cloned into a pAAV vector 
under the control of a CMV promoter (Addgene plasmid #36055; 
http://n2t.net/addge ne:36055; RRID: Addgene36055). The Vn-
α-syn (Addgene plasmid #89470; http://n2t.net/addge ne:89470; 
RRID:Addgene_89470) and α-syn-Vc (Addgene plasmid #89471; 
http://n2t.net/addge ne:89471; RRID:Addgene_89471) plasmid frag-
ments were both previously cloned into the backbone of pcDNA3.1 
under the control of a CMV promoter and were a kind gift of Tiago 
Outeiro. The α-syn-Venus (α-syn-V) construct encoding α-syn fused 
to full-length Venus under the control of a CMV promoter in a pcDNA 
3.1 backbone was a kind gift from Pamela McLean. BacMam viral plas-
mids & production was performed by Oxford Expression Technologies 
(OET) using the template DNA from Addgene plasmids #89470 
& #89471. Takara Clontech pTRE3g bidirectional plasmid (Takara 
Clontech Cat# 631,337) for inducible expression was subcloned from 
Addgene plasmids #89470 & #89471. Further details about each vec-
tor and the full sequences can be obtained upon request (Table S1).
2.2 | Cell culture and transfection protocol
HEK-293 cells were maintained in Dulbecco's modified Eagle me-
dium (DMEM; Gibco, Cat# 31966-021) containing 10% FBS and 
streptomycin and penicillin (10 μg/ml) at 37°C. The maximum num-
ber of passages was 15. Cells were transfected by the addition of 
polyethylenimine (PEI) (Polysciences Inc, Cat# 23966) to plasmid 
DNA in Opti-MEM (Gibco, # 31985-062) at a ratio of 1:3 (μg vector 
DNA:μg PEI). The added transfection mixture volume was 10% of 
the total volume of the cell culture medium present in each well. The 
amount of plasmid DNA used for transfection was 2 µg for six-well 
plates and 10 µg for 10 cm dishes. For BiFC co-expression (Vn-α-syn 
and α-syn-Vc), 1 µg of each BiFC vector was used for six-well plates 
and 5 µg of each vector was used for 10 cm dishes.
Induced expression of the bidirectional plasmid required the use 
of HEK 293 Tet-On® 3G cells (Takara Clontech Cat# 631182). Cells 
in six-well plates were transfected with 1 µg of the bidirectional plas-
mid using lipofectamine 3000 (Thermo Fisher Scientific Cat# L3000-
008) as per the manufacturer's instructions. Twenty-four hour after 
transfection expression was induced with 1 µg/mL doxycycline.
For BacMam viral studies, SH-SY5Y (ECACC) neuroblastomas 
were maintained in 1:1 DMEM:F12 (Thermo Fisher Scientific Cat# 
11-039-021) containing 10% FBS and streptomycin and penicil-
lin (10 μg/ml) at 37°C. The maximum number of passages was 20. 
BacMam virus was added at a multiplication of infectivity of 200 
according to viral titre determined by OET.
For BiFC expressing cell lines, SH-SY5Y (ECACC) neuro-
blastomas stably expressing either Vn-α-syn or α-syn-Vc were 
maintained in DMEM-Glutamax (Thermo Fisher Scientific Cat# 
1056601610566016) containing 10% FBS, streptomycin and peni-
cillin (10 μg/ml) and Geneticin (300 μg/ml) at 37°C. The maximum 
number of passages was 10. SH-SY5Y (ECACC) cell lines that either 
stably expressed Vn-α-syn or α-syn-Vc were a kind gift from Dr 
Seung-Jae Lee (Bae et al., 2014).
2.3 | Preparation of α-syn fibrils
Pre-formed fibrils (PFFs) were generated, characterized and used 
in the neuronal seeding model as described previously in (Mahul-
Mellier et al., 2020).
2.4 | Immunocytochemistry
HEK-293 cells (300,000 cells per well in 2 ml cell medium) were 
seeded onto coverslips coated with poly-l-lysine (Cultrex, Cat# 
3438-100-01) and transfected as described above. Cells were 
washed two times with PBS and fixed in 3.7% formaldehyde (Sigma 
Aldrich) at RT for 15 min. Cells were then blocked and permea-
bilized simultaneously in PBS containing 3% BSA and 0.1% Triton 
X-100 (PBS-T) at RT for 30 min. α-syn was targeted using the Syn-1 
antibody (BD Biosciences) in PBS-T (diluted 1:500) and the α-syn 
pSer129 antibody MJF-R13 (Abcam, ab168381) at RT for 2 hr. 
Cells were then rinsed five times with PBS-T and incubated with 
a cocktail of donkey anti-mouse Alexa Fluor 647 (1:800), donkey 
anti-rabbit Alexa Fluor 568 (1:800) and DAPI (1:1,500) in PBS-T at 
RT for 1 hr. Cells were then washed four times in PBS-T and finally 
rinsed with pure water before being mounted in polyvinyl alcohol 
(PVA) mounting medium with DABCO (Sigma Aldrich, Cat# 10981). 
Images of cells were captured with a confocal laser scanning micro-
scope using a 40x oil objective and Zen software (LSM 700, Zeiss).
As positive control for the analysis of α-syn inclusion formation, 
primary hippocampal neurons were treated with PFFs for 14 days 
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to induce the formation of α-syn inclusions. In this model, the mon-
itoring of pS129, ubiquitin, p62 and Thioflavin S positive inclusions, 
as reported previously (Mahul-Mellier et al., 2020), enabled us to 
validate the protocols used to assess the aggregation state and amy-
loid-like properties of α-syn in the BiFC cellular assays.
2.5 | Cell lysis
HEK-293 or SH-SY5Y cells were plated in six-well plates (300,000 
cells per well in 2 ml cell medium) and lysed in RIPA buffer (150 mM 
NaCl, 50 mM Tris pH 8.0, 1% NP-40, 0.5% deoxycholate, and 0.1% 
SDS) supplemented with 1% protease cocktail inhibitor (Sigma 
Aldrich, Cat# PB8340) and 1% phenylmethylsulfonyl fluoride (Axon 
Lab, Cat# A0999.0005) 48 hr after transfection. The cell suspension 
was then gently mixed while being rotated at 4°C for 30 min, and 
the cell debris was pelleted afterwards by centrifugation at 4°C and 
13,000 g for 20 min. The supernatant fraction was then used for 
immunoblotting.
For analysis of the SDS-insoluble fractions, the samples were 
centrifuged for 30 min at 13,000 g instead of 20 min, and the insol-
uble fraction (pellet) was resuspended in TBS/SDS buffer (150 mM 
NaCl, 50 mM Tris, pH 7.5 and 2% SDS) and sonicated using a probe 
for 15 s (1 s on pulse/1 s off pulse) at a 20% amplitude. The soluble 
and insoluble fractions were then processed as described in the im-
munoblotting section.
2.6 | Immunoblotting procedure
The total protein concentration for each sample was determined by 
the bicinchoninic acid assay (BCA, Thermo Scientific, Cat# 23225). 
Samples were next mixed (4:1) with 4x Laemmli buffer (2% sodium do-
decyl sulphate (SDS), 20% glycerol, 0.05% bromophenol blue, 0.125 M 
Tris-HCl pH 6.8 and 5% β-mercaptoethanol). Samples were not boiled 
to maintain the stability of the protein interactions. Total cell lysates 
(10 µg) were separated with 15% SDS-PAGE (polyacrylamide gel elec-
trophoresis) and transferred to a nitrocellulose membrane (Chemie 
Braunschweig, Cat# MSNC02030301) with a semidry system (BioRad, 
Cat# 1704150) at a constant amperage of 0.5 A and 25 V for 45 min. 
The membranes were then blocked with Odyssey Blocking buffer (Li-
Cor, Cat# 927-40000) that was diluted 1:3 in PBS at 4°C overnight. The 
membranes were then probed with the respective primary antibody 
(1:1,000 diluted in PBS) on a shaking platform at RT for 2 hr and then 
washed three times for 10 min in PBS-T (PBS, 0.1% Tween 20). The 
membranes were next incubated with the respective Alexa-conjugated 
secondary antibodies (goat anti-mouse IgG Alexa Fluor 800 or goat 
anti-rabbit IgG Alexa Fluor 680; 1:5000 in PBS) on a shaking platform 
while protected from light at RT for 1 hr. The blots were finally washed 
three times in PBS-T and scanned by an Odyssey CLx Imaging System 
(Li-Cor Biosciences) at a wavelength of 700 or 800 nm.
For BacMam-transduced samples in SH-SY5Y cells the above 
protocol was followed with the following exceptions. For native 
gel experiments 15 µg of each sample were mixed with native 
sample buffer (BioRad, Cat # 1610738) and loaded on NuPAGE 
4%–12% Bis-Tris gels (Thermo Scientific, Cat# NP0335BOX) with 
Tris-Glycine running buffer (BioRad, Cat# 1610734). Total protein 
was detected on the gel using InstantBlue Protein Stain (Expedeon 
Cat# ISB1L-EXP-1L) before fluorescence was visualized using a GE 
Amersham Typhoon (GE Healthcare Lifesciences) with the GFP 
filter set. Protein was then transferred to PVDF (BioRad Cat# 
1704157) using a BioRad TurboBlot. Membranes were blocked 
with 5% milk and incubated with primary antibody diluted in block-
ing buffer at 4°C overnight. For non-native experiments 15 µg of 
each sample were mixed with 4 x XT sample buffer (BioRad, Cat 
#1610791), loaded on Criterion XT 4%–12% Bis-Tris gels (BioRad, 
Cat# N3450124) with NuPAGE MES-SDS running buffer (Thermo 
Scientific, Cat# NP000202).
2.7 | Crosslinking of intact cultured cells
Cells cultured in six-well plates (300,000 cells in 2 ml medium) were 
removed from the plate by enzymatic digestion via trypsinization 48 hr 
post-transfection and collected by centrifugation of the cells at 300 g 
and RT for 3 min. Subsequently, the cells were resuspended in 600 µl 
of PBS containing protease inhibitors (Roche, Cat# 05892791001) 
and split into two 300 µl aliquots. One aliquot was treated with DSG 
(disuccinimidyl glutarate) crosslinker (1 mM) (Thermo Scientific, Cat# 
20593) and the other served as a DMSO only negative control. DSG 
was stored at 4°C with desiccant and prepared fresh directly before 
use by dissolving it in DMSO to make a 100 mM solution (100x stock 
solution). Crosslinking was performed under shaking conditions at 
750 rpm for 30 min at 37°C. The reaction was then quenched by add-
ing Tris (50 mM, pH 7.6) and incubating at RT for 15 min. Next, the 
cells were lysed by sonication (amplitude of 40%, 2 × 15 s) and centri-
fuged at 20,000 g for 30 min at 4°C. The supernatant was collected, 
and total protein concentration determined by BCA. The sample was 
then mixed 1:1 with NuPAGE LDS sample buffer (Thermo Scientific, 
Cat# NP0007) and boiled at 95°C for 10 min. Twenty micrograms of 
each sample was run on NuPAGE 4%–12% Bis-Tris and proteins were 
electroblotted onto PVDF membranes (Millipore, ISEQ00010), which 
were further processed as described in the immunoblotting section.
For BacMam-transduced samples in SH-SY5Y cells the above 
protocol was followed with the following exceptions. Samples were 
cross-linked in plate, mixed with BioRad XT sample buffer (BioRad 
Cat# 1610738) and resolved on BioRad Criterion 4%–12% precast 
gels (BioRad Cat# 3,450,125) before being transferred to PVDF 
(BioRad Cat# 1704157) using a BioRad TurboBlot.
2.8 | Size exclusion chromatography
Cells were plated in 10 cm dishes (2.2 × 106 cells) and transfected 
as previously described. Cells were lysed 48 hr post-transfection by 
nonionic detergent lysis buffer (20 mM Tris pH 7.4, 150 mM NaCl, 
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1 mM EDTA, 0.25% NP40 and 0.25% Triton X-100) supplemented 
with 1% protease cocktail inhibitor (Sigma Aldrich, Cat# PB340) and 
1% phenylmethylsulfonyl fluoride (Axon Lab, Cat# A0999.0005) 
under gentle rotation for 30 min at 4°C. Cell lysates were then 
cleared by centrifugation at 13,000 g for 30 min at 4°C, and 300 µl of 
the collected supernatant was directly injected onto a Superdex 200 
HR 10/300 column (GE Healthcare Life Science, Cat# 17517501). To 
avoid any aggregation artefacts because of freezing and thawing of 
the samples, the cell lysates were directly subjected to size exclusion 
chromatography using an ÄKTA purifier (GE Healthcare Life Science). 
The column was washed with three column volumes (75 ml) of Milli-Q 
and equilibrated with three column volumes of filtered PBS (20 mM 
sodium phosphate, 150 mM NaCl, pH 7.4) at a flow rate of 0.3 ml/min. 
An injection loop with a 500 µl volume was used to introduce the ana-
lytes and washed with 5 ml of buffer manually using a plastic syringe 
before each run. The flow rate for each run was set to 0.5 ml/min at 
4°C, and the collection volume was set to 500 µl. From each size frac-
tion, a 40 µl aliquot was directly mixed with 10 µl of 4x Laemmli buffer 
(2% sodium dodecyl sulfate (SDS), 20% glycerol, 0.05% bromophenol 
blue, 0.125 M Tris-HCl, pH 6.8 and 5% β-mercaptoethanol) and each 
sample was then subjected to immunoblotting as described in the 
corresponding section. For calibration, the Superdex 200 column was 
calibrated using a gel filtration HMW calibration kit (GE Healthcare 
Life Science, Cat# 28403842) that included six reference proteins 
with known molecular weights (MWs) (ranging from 43–669 kDa). 
The generated standard curve allowed us to calculate the apparent 
MW of each eluted α-syn construct (Figure 2c). Dextran blue 2000 
produced a peak at 7.78 ml, which defined the void volume (Vo) and 
thereby the maximal size of the proteins that could be separated 
(Figure 2b).
2.9 | Statistical analysis
The level of the corresponding α-syn constructs were estimated 
by measuring the WB band intensity using Image J software (U.S. 
National Institutes of Health, Maryland, USA; RRID:SCR_001935) 
and normalized to the relative protein levels of actin or GAPDH. The 
statistical analyses were performed using the ANOVA test followed 
by a Tukey–Kramer post-hoc test using Graph Pad Prism v.8.4.2. The 
data were regarded as statistically significant at p < .05.
3  | RESULTS
3.1 | The two α-syn-Venus BiFC fragments were 
expressed at different levels
As a first step in characterizing the Venus-α-syn BiFC system, 
we sought to assess the protein levels and stability of full-
length α-syn either fused to the individual fragments (Vn-α-syn 
or α-syn-Vc) or full-length Venus (α-syn-Venus). The constructs 
corresponding to these proteins were overexpressed in HEK-293 
cells, and the cell lysates were analysed by western blotting (WB) 
with antibodies against α-syn as well as the N- and C-terminal 
fragments of Venus (abbreviated as Vn-α-syn and α-syn-Vc, 
respectively). Both the full-length α-syn-Venus and Vn-α-syn 
protein levels were high, whereas the band corresponding to 
α-syn-Vc was barely detectable in comparison to that of Vn-α-
syn (Figure 2a). When expressed individually, Vn-α-syn was ex-
pressed at 6- to 16-fold higher levels than α-syn-Vc (Figure 2a) 
and at levels higher than those of any of the other tested con-
structs (WT-α-syn, α-syn-Vc and α-syn-Venus), suggesting an 
increased stability or decreased turnover of Vn-α-syn that is 
consistent with previous observations (Dominguez-Meijide 
et al., 2020; Eckermann, Kügler, & Bähr, 2015; Gustafsson 
et al., 2018; Lázaro et al., 2014).
When the two constructs were co-expressed, the α-syn-Vc pro-
tein band became undetectable, while a new band corresponding to 
the Vn-α-syn + α-syn-Vc dimer was detected. This is consistent with 
previous reports demonstrating irreversible dimerization of proteins 
upon successful reconstitution by BiFC (Hu et al., 2002). However, 
the band intensity of Vn-α-syn remained at a level that is compara-
ble to that observed when the protein was expressed alone. These 
results suggest that only a small fraction of Vn-α-syn associates with 
α-syn-Vc to form the fluorescent BiFC complex.
To assess whether it would be possible to increase the levels of 
α-syn-Vc and achieve an equimolar concentration of both BiFC con-
stituents, we varied the amounts of vector DNA applied for trans-
fection. As expected, the protein level of WT-α-syn was increased 
with the increasing amount of vector DNA used for transfection 
(Figure 2c). But, strikingly, despite the transfection of six times more 
α-syn-Vc than Vn-α-syn, the levels of α-syn-Vc remained unchanged 
(Figure 1 Figure 2c and d). In parallel, we created a bidirectional ex-
pression system (pTRE3G-Bi Takara Clontech) that allowed for the 
inducible expression of both BiFC subunits fused with α-syn under 
the control of a single promoter (Figure 2e). Upon transient trans-
fection of this plasmid into HEK293 Tet-On cells (Takara Clontech) 
expression of both α-syn-Vc & Vn-α-syn was induced with 1 μg/mL 
doxycycline. Despite controlling expression in this manner an imbal-
ance of protein expression was still observed with Vn-α-syn still being 
the dominant species (Figure 2e). Surprisingly, this imbalance has 
been repeatedly observed but not discussed in previous studies (Cai 
et al., 2018; Dominguez-Meijide et al., 2020; Eckermann et al., 2015; 
Gustafsson et al., 2018; Lázaro et al., 2014, 2016; Prasad et al., 2018; 
Zondler et al., 2014). Only one report (Eckermann et al., 2015) sug-
gested that the differential expression of the two constructs could 
lead to a potential entrapment of α-syn-Vc by the strongly overex-
pressed Vn-α-syn and force the less abundantly expressed protein 
into an non-specific interaction.
These data were consistent in orthogonal experiments includ-
ing BacMam viral delivery of Vn-α-syn & α-syn-Vc into SH-SY5Y 
cells (Figure 3). Whilst the α-syn-Vc protein band in this system was 
not reduced to a level that was undetectable, there was a consis-
tently higher expression of Vn-α-syn over α-syn-VC across multi-
ple time points ranging from 24 hr to 72 hr after exposure to virus 
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F I G U R E  2   The two BiFC fragment proteins are not expressed at the same level in HEK-293 cells. (a) HEK-293 cells overexpressing 
distinct α-syn constructs were lysed 48 hr after transfection, and the cell lysates were analysed by immunoblotting for α-syn (Syn-1), without 
boiling. GAPDH was used as the loading control. A representative blot of n = 3 experiments is shown (b). Densitometry of data shown in (a); 
a significant difference was indicated (p = .045) by one-way ANOVA followed by a Tukey test for BiFC (Vn-α-syn) versus BiFC (α-syn-Vc). (c) 
WB of lysates from HEK-293 cells transfected with various amounts of vector α-syn DNA (depicted above the blot). α-syn was detected by 
anti-α-syn (Syn-1). The samples were boiled to disrupt complex formation to allow accurate determination of the levels of the two fragments. 
(d) Relative protein levels (α-syn/β-tubulin) of BiFC proteins determined by quantification of the respective bands in (d) using Image Studio 
Lite. Data are shown as the mean of three independent experiments, each performed as technical duplicates (error bars represent the SD). 
(e) Schematic of bidirectional inducible plasmid for expression of Vn-α-syn & α-syn-Vc under the control of a single tetracycline promoter. 
Immunoblot showing expression of both Vn-α-syn & α-syn-Vc upon addition of 1 μg/mL doxycycline. Samples were boiled prior to SDS-PAGE. 
No relevant significant difference was observed between the tested conditions using one-way ANOVA followed by a Tukey test. Vn-α-syn: 
(amino terminal fraction of Venus)-α-syn; α-syn-Vc: α-syn- (carboxy terminal fraction of Venus); α-syn-V (α-synuclein-Venus full length)
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(Figure 3b). Venus fluorescence of BacMam delivered proteins 
resolved on a native-PAGE gel primarily revealed a small propor-
tion of Vn-α-syn and α-syn-Vc dimer (compared to BacMam GFP) 
(Figure 3c). Transfer of these proteins to a membrane and subse-
quent probing for α-syn by WB showed that only small amounts of 
the total α-syn correlated with the Vn-α-syn and α-syn-Vc dimer 
band that was fluorescent. This confirmed that only a small propor-
tion of Vn-α-syn and α-syn-Vc dimerised into a form detectable by 
Venus fluorescence.
3.2 | Vn-α-syn exhibits a high propensity to form 
oligomers and higher-order aggregates
Next, we sought to investigate the biochemical and oligomeriza-
tion properties of each of the BiFC fragments. Towards this end, the 
lysates of HEK-293 cells expressing the various α-syn BiFC proteins 
were separated by size exclusion chromatography (SEC). To assess 
whether any of the reagents or lysis of the cells affected size separa-
tion, the elution pattern of recombinant α-syn (Figure 4b, grey line) 
was compared to that of the lysate of WT-α-syn-expressing HEK-
293 cells (Figure 4b, orange line) via analysis of the eluates by WB. 
Note, the resulting UV chromatogram of the cell lysates mostly rep-
resented total proteins rather than α-syn, which is why WB analysis 
was crucial for the comparison of the elution pattern. The elution of 
α-syn at 13–14 ml for both samples suggested that intracellular α-syn 
exists predominantly as a monomer, which is consistent with previ-
ous findings (Fauvet et al., 2012; Weinreb, Zhen, Poon, Conway, & 
Lansbury, 1996).
The largest α-syn construct, α-syn-Venus, eluted from 8 to 15 ml 
with the most intense band detected at 11–13 ml (Figure 4b, green). 
This suggests that α-syn-Venus has a low propensity to form high-
er-order oligomers but that the majority of the protein exists in a 
monomeric form. Given that Vn-α-syn and α-syn-Vc have sizes that 
are between those of α-syn-V and WT-α-syn, we expected these 
proteins to elute at volumes between 8 ml and ~15 ml. As expected, 
α-syn-Vc eluted at 13 ml (Figure 4b, blue) but in contrast the major-
ity of Vn-α-syn eluted at the void volume of 7.5 ml (Figure 4b, red), 
indicative of the high propensity for this protein to self-oligomerize. 
When both BiFC constructs were present, the band corresponding to 
the size of Vn-α-syn still eluted mainly at the void volume (Figure 4b, 
yellow). Interestingly, co-expressed α-syn-Vc was now detected in 
higher MW fractions (<10 ml), possibly because of a shift caused by 
the dimerization of the BiFC constructs and consistent with what we 
observed by WB (Figure 2a). Furthermore, the detection of a band 
in the void volume corresponding to the BiFC-α-syn dimer complex 
suggested that this complex goes on to form higher-order oligomers 
or that it is sequestered by the aggregates formed by the Vn-α-syn 
fragment (Eckermann et al., 2015). Additionally, we also analysed the 
lysate of SH-SY5Y cells that stably expressed either the α-syn-Vc 
or Vn-α-syn constructs using SEC, which confirmed an intrinsically 
high aggregation propensity of Vn-α-syn in independent system 
(Figure S1).
3.3 | Crosslinking studies confirm that Vn-α-syn 
but not α-syn-Vc forms higher MW weight oligomers
To further characterize the aggregation propensities of the various 
α-syn BiFC fragments, we performed intact cell crosslinking and as-
sessed the oligomerization by WB. DJ-1, which forms dimers in physi-
ological conditions (Dettmer et al., 2015), was used as a positive control. 
Successful crosslinking within our experimental parameters was con-
firmed by the DSG-crosslinked cell lysate displaying a DJ-1 dimer band 
that was absent in non-crosslinked cells (Figure 5b). WT α-syn was 
mainly detected as a monomer (15 kDa), but a noticeable stochastic lad-
der of dimers, trimers and higher molecular weight (MW) species was 
also observed (Figure 5a). α-syn-Venus displayed two bands: one at the 
expected monomeric size of 42 kDa and one band at a lower size of 
approximately 36 kDa. The lower band was observed whenever the 
sample was not boiled prior to immunoblotting and is likely to represent 
a more compact folded structure of this fusion protein. In concordance 
with the SEC results, α-syn-Vc showed a single band at the expected 
MW, and no higher MW species were detectable. In contrast, Vn-α-syn 
formed several higher MW bands, including a prominent band that re-
mained in the stacking gel. These high MW aggregates were only ob-
served when intact cell crosslinking was performed. This suggests that 
in the absence of crosslinking, the majority of the Vn-α-syn oligomers 
are SDS-sensitive and break down into monomers in denaturing con-
ditions. Additionally, the stacking gel showed a high-molecular-weight 
signal for α-syn as a result of co-expression, despite the intensity of 
this band being weaker than when Vn-α-syn alone was expressed. The 
aggregation seen here is likely to be driven by Vn-α-syn, as α-syn-Vc 
alone did not produce any higher MW aggregates. DSG crosslinking ex-
periments were also performed in SH-SY5Y cells with BacMam virus 
mediated protein delivery (Figure 5c). These data confirmed the dif-
fering oligomerization properties of the Vn-α-syn & α-syn-Vc proteins. 
Furthermore, immunodetection of a FLAG epitope present only in the 
α-syn-Vc construct confirmed that α-syn-Vc exists primarily as a mono-
mer when crosslinked in the absence or presence of Vn-α-syn. Together, 
the results from the crosslinking and SEC experiments further establish 
that Vn-α-syn exhibits a high propensity to self-oligomerize and exists 
predominantly in oligomeric forms independent of α-syn-Vc.
3.4 | Vn-α-syn predominantly forms soluble SDS-
sensitive oligomers in cells
To determine whether the BiFC fragments form oligomers or higher-or-
der aggregates such as fibrils, the lysates from HEK-293 cells express-
ing the different proteins were separated by centrifugation (at 13,000 g 
for 20–30 min) into soluble and insoluble fractions (Figure 6a). This 
approach has been applied in previous studies to separate oligomeric 
and monomeric α-syn from insoluble α-syn species) (Fares et al., 2016; 
Lee, Khoshaghideh, Patel, & Lee, 2004; Savolainen et al., 2015). WB 
analyses showed that Vn-α-syn was predominantly detected in the 
soluble fraction (Figure 6b). This suggests that the self-assembled solu-
ble oligomers of Vn-α-syn that eluted in the void volume peak (7.5 ml) 
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of the SEC column (Figure 4b) are disassociated into monomers when 
in the presence of SDS (Figure 6b). In the insoluble fraction, the Vn-α-
syn fragment was also detected as monomer band, suggesting that a 
small proportion of this fragment goes on to form insoluble aggregates. 
In contrast, none of the other constructs, including α-syn-Vc, could be 
detected in the insoluble fractions. Consistent with the data presented 
above, the ratio of insoluble over soluble fraction was higher for Vn-
α-syn than for α-syn-Vc (Figure 6c). Interestingly, when the two BiFC 
fragments were co-expressed, only Vn-α-syn (identified by size) was 
sufficiently enriched in the insoluble fraction. Only traces of α-syn-Vc 
and the complexed BiFC could be detected in the insoluble fraction, 
this could be because of the fact that these species become entrapped 
within or non-specifically interact with the Vn-α-syn aggregates. Similar 
observations were found in SH-SY5Y cells stably expressing either the 
Vn-α-syn or α-syn-VC (Figure S2).
3.5 | Neither of the BIFC fragments when expressed 
alone or when co-expressed in cells form α-synuclein 
amyloid-like aggregates or inclusions
Finally, we sought to characterize the aggregation properties of 
the BiFC fragments in intact cells by immunocytochemistry. The 
proteins were expressed in HEK-293 cells, and their localization and 
aggregation were assessed using an α-syn specific antibody (Syn-
1). α-syn fused to full-length Venus was used as a positive control 
and untagged α-syn as a negative control. As expected, no Venus 
fluorescence was observed when the individual BiFC fragments, 
Vn-α-syn or α-syn-Vc, were expressed alone, while co-expression of 
both proteins led to intense signals from Venus as a result of com-
plementation (Figure 7). Fluorescence was observed both in the cy-
tosol and the nucleus, as previously reported (Dettmer et al., 2015; 
Lázaro et al., 2014, 2016; Moussaud et al., 2015). Consistent with 
the results from the biochemical and SEC studies, we did not ob-
serve the formation of foci or pSer129 positive inclusions for any of 
the BiFC constructs used, indicating that the BiFC fragments either 
alone or when co-expressed predominantly form soluble oligomers 
that do not exhibit amyloid-like properties, as evidence by the lack 
of binding to the amyloid-specific dye Amytracker (Figure S3). As a 
positive control, we used a primary neuronal α-syn seeding model 
where abundant α-syn fibrils are formed 7–14 days after treatment 
with preformed fibrils (PFFs). The α-syn aggregates in this neuronal 
seeding model are both pS129 and Amytracker positive, consist-
ent with previous reports by our group and others (Mahul-Mellier 
et al., 2020). Although previous studies did not report quenching of 
the Amytracker signal by a GFP tag (Frottin et al., 2019; Marrone, 
F I G U R E  3   The two BiFC fragment 
proteins are not expressed to the same 
level in BacMam transduced SHSY5Y 
cells. (a) Denaturing immunoblot of Vn-
α-syn & α-syn-Vc expression following 
BacMam virus mediated delivery in 
SH-SY5Y cells. Virus was added for 
24 hr, washed off and time 0 sample 
taken. Protein expression was tested 
24 and 48 hr after virus removal. (b) 
Quantification of data displayed in (a) 
using Image Studio Lite. Data are shown 
as the fold change Vn-α-syn normalised 
to α-syn-Vc (error bars represent the 
S.D.) at each time point. (c) Native-PAGE 
analysis of detectable fluorescence 
following 24 hr incubation with each 
respective BacMam virus. Samples were 
resolved by native-PAGE, equal protein 
loading confirmed with InstantBlue 
protein stain. In gel fluorescence imaged 
using a GE Amersham Typhoon Imager 
showing one main band for the Vn-α-syn 
& α-syn-Vc fluorescent dimer at a reduced 
intensity compared to BacMam-GFP 
virus. Immunoblot following transfer of 
native-PAGE to PVDF showing only small 
amount of Vn-α-syn & α-syn-Vc present as 
discrete dimer
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Qamar, Mannini, St George-Hyslop, & Vendruscolo, 2020; Rallis 
et al., 2020), we could not exclude that the presence of the Venus 
tag fused to α-syn could quench the fluorescence of Amytracker.
These observations demonstrate an absence of insoluble aggre-
gated or fibrillar forms of α-syn in cells expressing either or both of 
the BiFC fragments, suggesting that the oligomers formed by the 
F I G U R E  4   The Vn-α-syn fragment exhibits a high propensity to form soluble oligomers compared to α-syn-Vc and WT α-syn. (a) Size 
exclusion chromatography of a HEK-293 cell lysate 48 hr post-transfection with the indicated α-syn constructs. The SEC fractions were 
analyzed by WB using anti-α-syn (Syn-1) antibodies. (b) Calculated apparent MW depicted with a log scale plotted against the Kav value of 
each α-syn construct (large colored dots). Mixed circles represent either Vn-α-syn (red) or α-syn-Vc (blue) when being coexpressed. (c) Standard 
curve generated using the indicated six reference proteins. (d) Working model suggesting that the high propensity of Vn-α-syn to oligomerize 
and how such oligomers could interact with or entrap α-syn-Vc. Note, the UV280 signal in A does not correspond to the α-syn signal, but 
mostly proteins in the remaining cell lysate. Representative data shown from n = 3 experiments. Vo: dead volume; Ve: elution volume; Vn-α-
syn: (amino terminal fraction of Venus)-α-syn; α-syn-Vc: α-syn-(carboxy terminal fraction of Venus); α-syn-V (α-synuclein-Venus full length)
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individual or complexed Venus BiFC fragments do not go on to form 
fibrils and may not share properties with oligomers that are known 
to be part of the pathway to α-syn fibril formation. Further studies 
are needed to characterize the biochemical and structural properties 
of the α-syn oligomers formed by the BiFC fragments to determine 
the extent to which they resemble native α-syn oligomers.
4  | DISCUSSION
Several α-syn BiFC cellular assays (Gonçalves, Matos, & 
Outeiro, 2010) have been developed and are increasingly used in cel-
lular and animal studies aimed at identifying and validating the tar-
gets or mechanisms of α-syn aggregation, propagation and toxicity. 
These assays have also been used to identify genetic, enzymatic and 
pharmacological modulators of α-syn aggregation, toxicity and clear-
ance (Cai et al., 2018; Dimant et al., 2013; Eastwood, Baker, Brooker, 
Frank, & Mulvihill, 2017; Kiechle et al., 2019; Moussaud et al., 2015; 
Outeiro et al., 2008; Prasad et al., 2018). Despite this, there has been 
very little effort to validate these assays (Eckermann et al., 2015) at 
the biochemical level and to characterize the nature of the α-syn oli-
gomers that form upon reconstitution of the α-syn BiFC fragments 
and fluorescence signal. The primary objective of this study was to 
contribute to addressing this knowledge gap by (1) providing insight 
into the molecular interactions that give rise to the fluorescence sig-
nal observed in these assays; and (2) investigating the solubility and 
aggregation state of the α-syn BiFC fragments and complexes.
Our studies show that α-syn-Vc is expressed at levels that are 
significantly less than Vn-α-syn in various cellular systems using 
different methods of protein delivery, and that only a fraction of 
Vn-α-syn participates in the formation of complexes that give rise 
to the fluorescence signal. This discrepancy in protein expression 
levels between the two fragments has been consistently observed 
in previous studies (Bartels et al., 2019; Cai et al., 2018; Delenclos 
et al., 2019; Eckermann et al., 2015; Gonçalves et al., 2016; 
Gustafsson et al., 2018; Herrera & Outeiro, 2012; Lázaro 
F I G U R E  5   Intact cell crosslinking of α-syn BiFC constructs confirms SEC findings of Vn-α-syn oligomerization. (a) Living HEK-293 cells 
were crosslinked by the addition of DSG 48 hr post transfection with the indicated α-syn constructs, and the resulting cell lysate was 
analysed by Western blotting against α-syn using the Syn-1 antibody. All analysed α-syn proteins displayed higher MWs upon addition of 
the DSG crosslinker, except for α-syn-Vc. (b) The physiological dimer DJ-1 was used as an internal control so that the correct crosslinker 
concentration was applied. DJ-1 immunoblotting confirms that dimers are only detected upon crosslinking. (c) Immunoblot of DSG 
crosslinked to live SH-SY5Y cells following 24 hr BacMam delivery of either Vn-α-syn or α-Syn-Vc or both constructs. All displayed samples 
treated with DSG. Cells treated with only Vn-α-syn displayed higher order crosslinked oligomeric species in addition to monomeric Vn-α-syn. 
Cells treated with only α-syn-Vc displayed only monomeric α-syn-Vc. Treatment with both Vn-α-syn and α-Syn-Vc displayed higher order 
crosslinked oligomeric species in addition to both monomeric proteins. To determine if the higher order crosslinked oligomeric species in 
the sample treated with both Vn-α-syn and α-Syn-Vc were comprised of both proteins a separate WB for the FLAG epitope present only in 
the α-Syn-Vc protein was performed, this revealed the higher order crosslinked oligomeric species were predominantly comprised of Vn-
α-syn. EV: empty vector; Vn-α-syn: (amino terminal fraction of Venus)-α-syn; α-syn-Vc: α-syn-(carboxy terminal fraction of Venus); α-syn-V 
(α-synuclein-Venus full length). Blots are representative of n = 3 experiments
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et al., 2014, 2016; Moussaud et al., 2015; Prasad et al., 2018; 
Zondler et al., 2014), but rarely discussed or taken into account in 
the interpretation of the results from the BiFC assays. Despite our 
attempts to promoter, both proteins under a single Tet-On inducible 
promoter we could not overcome these differential expression is-
sues. Interestingly, even when the Venus-BiFC fragments were ex-
pressed in Drosophila, protein levels of the α-syn-Vc fragment were 
significantly lower compared to the Vn-α-syn fragment (Prasad 
et al., 2018). Despite this observation the authors in this study 
chose to quantify the levels of insoluble α-syn using a filter retarda-
tion assay, a procedure that does not allow for determining the na-
ture and distribution of the α-syn species in the insoluble fractions 
(i.e. the aggregates may consist purely of the aggregation-prone 
fragment Vn-α-syn or in complex with α-syn-Vc). In a further study, 
Kiechle et al. investigated age-dependent changes to α-syn oligom-
erization and aggregation at the synapse in two transgenic mouse 
models where α-syn was fused to the N- or C-terminal part of 
hGaussia Luciferase or YFP Venus halves (Kiechle et al., 2019). For 
F I G U R E  6   Vn-α-syn, but not α-syn-Vc or WT α-syn, is detected in the insoluble fractions. (a) HEK-293 cells overexpressing distinct α-syn 
constructs were lysed 48 hr after transfection, and the cell lysates were separated into a soluble and insoluble fraction by centrifugation. 
The resulting fractions were analysed by immunoblotting of α-syn (Syn-1). GAPDH was used as the loading control. Shown is a 
representative blot of n = 3 experiments. (b) Resulting soluble and insoluble band intensities of (a) were quantified and normalized to soluble 
GAPDH. Significant differences were indicated (p < .005) by one-way ANOVA followed by a Tukey test. (c) Ratio of insoluble to soluble 
α-syn of Vn-α-syn and α-syn-Vc. Vc EV: empty vector; Vn-α-syn: (amino terminal fraction of Venus)-α-syn; α-syn-Vc: α-syn-(carboxy terminal 
fraction of Venus); α-syn-V (α-synuclein-Venus full length)
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the hGaussia Luciferase protein-fragment system, the two com-
plementation fragments were expressed at different levels but for 
the Venus system, the author presented data that showed the two 
BiFC fragments both equally and differentially expressed. In the 
cases when expression was differential, findings were consistent 
with ours as levels of α-syn-Vc were reduced.
A possible explanation for the difference in protein levels could be 
because of the arrangement of the BiFC fusion proteins (Figure 1a); 
the split Venus fragments fused at the opposite ends of α-syn may 
influence α-syn stability or clearance. Similar to α-syn, differences 
in protein expression levels have also been consistently observed 
when Venus-BiFC is fused with the amyloid precursor protein (APP) 
(So, Khodr, Chen, & Abraham, 2013) and exon1 of the huntingtin 
protein (Httex1) (Herrera, Tenreiro, Miller-Fleming, & Outeiro, 2011) 
but not in the Luciferase- or GFP-based BiFC systems when both 
complementation constituents are fused to the carboxy-terminus 
of α-syn (Mohammadi et al., 2017; Moussaud et al., 2015; Outeiro 
et al., 2008). The large differences in the protein levels of the two 
Venus BiFC fragments combined with the high aggregation propen-
sity of Vn-α-syn highlight the critical importance of assessing the 
expression and aggregation state of each component in the Venus 
BiFC systems as well as other BiFC systems to ensure accurate inter-
pretation of experimental findings. In the absence of such insight, it 
is difficult to correlate the differences in the fluorescence signal to 
the propensity of α-syn to oligomerize or to speculate on the mech-
anisms of α-syn oligomerization, aggregation and toxicity in these 
cellular assays. This is especially important when the fluorescence 
signal arises from only a small fraction of the total α-syn expressed in 
the cell. Finally, whether the oligomers formed by Vn-α-syn could in-
fluence α-syn cellular properties in cellular assays using Venus-BiFC 
system remains unknown (Kiechle et al., 2019; Zondler et al., 2014). 
Together, these observations underscore the limitations of relying 
solely on the fluorescence signal as the primary readout of α-syn 
oligomerization.
Although previous studies did not thoroughly investigate 
the oligomerization properties of the individual BiFC fragments, 
two studies showed by denaturing (Roberts, Wade-Martins, & 
Alegre-Abarrategui, 2015) and native gel electrophoresis (Outeiro 
et al., 2008; Roberts et al., 2015) that some GFP-BiFC fragments 
have the propensity to form high molecular weight oligomers on 
their own (Kerppola, 2008). Despite the fact that in both these stud-
ies and a previous report (Magliery et al., 2005) the fragment with 
GFP/Venus fused to the N-terminus of α-syn exhibited increased 
oligomer formation, the significance and implications of these ob-
servations were not discussed or accounted for in the interpretation 
of the results. In another study by Dettmer and colleagues, intact 
cell crosslinking followed by WB analysis showed the presence 
HMW species corresponding to Vn-α-syn only, which is again con-
sistent with our findings (Dettmer et al., 2015). Furthermore, Bae 
et al. showed that only Vn-α-syn was secreted by cells and existed 
as a mixture of monomers and aggregates in the cell culture medium 
(Bae et al., 2014), consistent with our data (Figure 4a). When the cell 
culture media containing Vn-α-syn monomers and aggregates were 
added to cells stably expressing α-syn-Vc, fluorescent foci were ob-
served in the host cells. If the Vn-α-syn aggregates were removed 
prior to addition to other host cells, no BiFC signal was observed. 
These observations suggest that the fluorescence signal observed 
in the host cell arise because of the recruitment and/or entrapment 
of the α-syn-Vc monomers in the preformed Vn-α-syn aggregates 
rather than interactions between the two monomers, consistent 
with our observations and those of a previous report (Eckermann 
et al., 2015). This experiment illustrates the challenges in interpret-
ing BiFC fluorescence signal in systems where different BiFC frag-
ments exhibit differences in protein levels, biophysical properties 
and aggregation propensity and where aberrant interactions, in 
addition to the expected multimerization may give rise to the BiFC 
fluorescence signal.
One way to validate the cellular BiFC-based oligomerization as-
says is to assess the specificity of the interactions using mutant forms 
of the protein of interest that exhibit no, or a very low, propensity to 
self-associate or using closely related proteins that do not interact with 
one another or self-oligomerize (Hu et al., 2002; Kudla & Bock, 2016). 
In these cases, one would expect no, or very little, fluorescent signal 
when compared to that of BiFC protein partners that do oligomerize. 
Indeed, this approach has already been applied by several groups to 
investigate the utility of the Venus BiFC system to compare the oligo-
merization properties of the different members of the α-syn family 
(Eckermann et al., 2015) and various α-syn disease-associated mu-
tants (Dettmer et al., 2015; Lázaro et al., 2014, 2016). For example, 
Eckermann and colleagues reported no detectable differences in the 
Venus BiFC signal when α-, β- and ɣ-syn oligomerization were assessed 
in parallel, suggesting that they exhibit similar homodimerization prop-
erties (Eckermann et al., 2015). This is surprising, as β-syn is known to 
not aggregate, does not form inclusions in cells or the brain and has 
consistently been shown not to form fibrils under physiological con-
ditions (Ghosh et al., 2015). Similarly, one would expect an increased 
BiFC signal when using proteins with disease-specific point mutations 
such as A53T, that promote α-syn aggregation. Although several α-syn 
PD-associated mutants have been shown to promote α-syn oligomer-
ization and/or fibril formation in vitro (de Oliveira & Silva, 2019; Ruf 
et al., 2019), in cells (Fares et al., 2014; Khalaf et al., 2014; Lei, Cao, 
& Wei, 2019) and in vivo (Mbefo et al., 2015; Paumier et al., 2013), 
Lázaro et al. reported identical Venus BiFC signals from WT α-syn and 
the PD-linked mutants A30P, E46K, H50Q, G51D and A53T (Lázaro 
et al., 2014). Similar observation were made by Outeiro et al using a 
GFP-BiFC cellular assay (Outeiro et al., 2008). It was suggested that 
these observations could be explained by the possibility that the di-
merization propensity of the α-syn proteins does not reflect their 
oligomerization and aggregation properties (Eckermann et al., 2015). 
However, this interpretation is not consistent with extensive biophys-
ical studies using alternative approaches that show significant dif-
ferences in the propensity of α-syn with the various PD-linked α-syn 
mutants to form oligomers (Winner et al., 2011) and dimers (Janowska, 
Wu, & Baum, 2015; Lv et al., 2016). In addition, several studies have 
shown significant differences in the lifetime and distribution of differ-
ent types of dimers formed by wild-type α-syn and PD-linked mutants 
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(Krasnoslobodtsev et al., 2013; Krishnan et al., 2003; Lv et al., 2015). 
Taken together, these results demonstrate that the current α-syn BiFC 
cellular assays are not predictive of the propensity for α-syn to form 
oligomers or fibrils. Fundamentally, these data highlight that the α-syn 
BiFC assay is limited to specific protein conformations and many of 
these are not visible during detection because of the nature of bi-
fluorescent complementation. If used in a drug discovery setting to 
identify or investigate inhibitors or modifiers of α-syn dimerization/
oligomerization, there is a high risk that active compounds may pres-
ent as false negatives, which would likely result in poor translation of 
drug activity in other preclinical models.
Despite these limitations, several studies have demonstrated that 
the α-syn BiFC system could be useful to investigate α-syn cell-to-cell 
transmission (Bae et al., 2014; Danzer et al., 2011; Kim et al., 2016; 
Wang et al., 2014). In these experiments, each BiFC fragment is 
expressed in different cells which are then co-cultured and α-syn 
cell-to-cell transfer is monitored by the reconstitution of the BiFC 
fluorescence signal in either cell. In such studies, it is again crucial to 
biochemically assess the aggregation state of the BiFC fragment that 
is formed and secreted by each cell lines. These recommendations are 
in line with those made previously by Eckermann et al., (2015).
5  | CONCLUSIONS
The design of BiFC systems to investigate protein-protein interactions 
or protein self-assembly is based on three assumptions (1) the individual 
reporter fragments do not self-associate unless the proteins they are 
fused to interact with each other or have the propensity to dimerize or 
oligomerize (Kerppola, 2006); (2) both BiFC fragments are expressed at 
equal levels; and (3) mutants that disrupt or enhance protein–protein in-
teractions should result in a decrease or an increase in the fluorescence 
signal, respectively. While our studies confirm that a fluorescence signal 
is observed only when both BiFC fragments fused to α-syn are co-ex-
pressed in the cell, they also clearly demonstrate that (1) the Vn-α-syn 
and α-syn-Vc BiFC fragments are not expressed at equal levels; (2) the 
Vn-α-syn fragment exhibits a high propensity to aggregate; and (3) the 
fluorescence signal observed may not arise only from α-syn dimerization 
and could also be derived from the association or entrapment of α-syn-Vc 
in the Vn-α-syn aggregates. Together, these observations combined with 
previous findings from independent groups demonstrate that the α-syn-
Venus-BiFC system does not reveal known differences in the oligomeri-
zation and aggregation propensities of PD-associated variants or the 
interactions between mutants and WT α-syn (Eckermann et al., 2015). 
Finally, consistent with previous reports, we showed that overexpres-
sion of either Vn-α-syn or the two BiFC fragments results in the for-
mation of α-syn oligomers that do not seem to convert to inclusions or 
amyloid-like aggregates (Dettmer et al., 2015; Gonçalves et al., 2016; 
Kiechle et al., 2019; Lázaro et al., 2014; Moussaud et al., 2015; Outeiro 
et al., 2008). Together, these findings underscore the critical importance 
of characterizing BiFC-based cellular assays at the biochemical and struc-
tural levels and understanding how the fusion of fragments of fluorescent 
proteins influences α-syn biophysical and cellular properties before using 
such assays in mechanistic, target validation and drug discovery studies.
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